|2005N-0354||Consumer-Directed Promotion of Regulated Medical Products; Part 15 Public Hearing|
|FDA Comment Number :||EC243|
|Submitter :||Dr. Everett Mobley||Date & Time:||12/07/2005 06:12:54|
|Organization :||Dr. Everett Mobley|
|Category :||Health Professional|
| It is unethical and misleading for psychotropic drug advertisements to: 1. present themselves as a person's case history, and then footnote sotto voce that the individual is "not a real person". 2. Similarly, and much worse, to note in small print or sotto voce that "nobody knows what causes depression or how this drug works", and then to loudly, or in large print, proclaim that the drug "works" by correcting some mythical chemical imbalance. Note the article appearing on page B1 of November 18th's Wall Street Journal. "...we know slightly more than jack about how these drugs work." This is hardly new information (or lack of it), as cognitive neuroscience researchers have never claimed more than rudimentary knowledge of brain function,chemistry, development, and healing. It is only the psychiatric and pharmaceutical industries who persist in promoting these myths solely for profit.
It should be illegal to present as fact a completely unproven theory in a consumer-directed pharmaceutical advertisement.